03.05.2010 • News

Lyondell Chemical Emerges from Bankruptcy

Lyondell Chemical  said on Friday that it has exited bankruptcy after a 16-month process during which its debt load was reduced to about $5 billion from $24 billion.

The company, which went bankrupt last January after a drop in business due to the economic downturn left it unable to make debt payments, was able to make the move through financial backing from two private equity firms and industrial holding company Access Industries.

Access, owned by financier Len Blavatnik, had taken Lyondell private in 2007. He has bought back into the new company through a $2.8 billion rights offering and will own a small stake alongside Apollo Management and Ares Management.

Lyondell also said it raised $3.25 billion of first priority debt. The new company, LyondellBasell Industries NV based in the Netherlands, said it expects to begin trading on the New York Stock Exchange by the third quarter of this year. LyondellBasell said it has $5.2 billion in net consolidated debt and about $3 billion in liquid assets.

The move comes after the company fended off a takeover attempt by India's Reliance Industries earlier this year. It also settled hundreds of environmental claims.

Company contact







Interview

Driving Sustainability Through Collaboration
Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read